Advances in the pharmacological and neurological treatment of patients with multiple sclerosis.

Multiple sclerosis (MS) is an acquired inflammatory demyelinating disease of the central nervous system (CNS) believed to be of autoimmune pathogenesis. Progressive MS is a common cause of disability in young adults in the United States. Although several immunomodulating therapies have been tested in clinical and animal studies, there is no known treatment that prevents further progression and disability. Current research efforts are being focused on the development of novel, safe immunospecific treatments. Until such therapies become available, a major component of patient management should be to relieve symptoms, prevent complications, and maximize function in activities of daily living. A team approach involving health care professionals of various specialties is ideal for the management of patients with progressive MS.